



# EXPANDED ACCESS POLICY

## Expanding Patient Access to RhoVac's Investigational Medicines

### About RhoVac

RhoVac is dedicated to developing a cancer therapy that targets metastatic cells to prevent cancer recurrence and progression after primary tumour therapy and have the potential to transform the lives of patients suffering from life threatening diseases. We are committed to bring this important and innovative product to patients, and we believe in collaborating with families, patient advocacy organizations, physicians, researchers and regulatory authorities to accomplish this goal.

### RhoVac's investigational medicine in clinical trials

Evaluation of an investigational therapy in clinical trials, which are designed to gain an understanding of the safety and efficacy of the therapy in a specific population, is the optimal way to collect the information necessary to enable regulatory authority review and, ultimately, to bring a therapy to the entire patient community.

Participation in a clinical trial is also the best way for an individual patient to access an investigational therapy for his/her disease. Clinical trials generate data regarding the efficacy and safety of the investigational medicinal product and those data help inform regulatory authorities whether the benefits of the investigational medicinal products outweigh the risks. The ultimate goal is to secure regulatory approval and enabling the medicine to be available to as many patients as possible as quickly as possible.

### Statement

We understand that patients and families may be interested in accessing RhoVac's investigational therapies prior to regulatory approval and outside of the clinical trial setting through an expanded access program, also referred to as compassionate use trials or early access.

After carefully reviewing considerations for expanded access, RhoVac has determined that it cannot offer its drug candidates for expanded access at this time. We believe that continuing and focusing on our clinical trials is the most appropriate path forward for bringing our drug candidates to patients as quickly and safely as possible. The status of expanded access restriction will be re-evaluated at later development stages.

If you or a family member would like to learn more about RhoVac's investigational cancer therapy undergoing clinical trials, we encourage you to contact your physician to see if you are a candidate for one of our trials. You may also find helpful information regarding RhoVac's clinical trials on



[www.clinicaltrials.gov](http://www.clinicaltrials.gov). If you have any questions about RhoVac's expanded access policy, please contact us by E-mail at [info@rhovac.com](mailto:info@rhovac.com)